As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of CASI Pharmaceuticals, Inc. The largest reported stake is WEI-WU HE, Ph.D.'s, at 58.8%. 16 filings are on record since July 23, 2025 (Schedule 13D/A, May 18, 2026).
Sell to companies like CASI Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: WEI-WU HE, Ph.D. · Percent: 58.8% · Shares: 23,985,535 · SCHEDULE 13D/A
- · Holder: WEI-WU HE, Ph.D. · Percent: 53% · SCHEDULE 13D/A
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 9.2% · SCHEDULE 13G/A
- · Holder: Foresite Capital Fund VI LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: WEI-WU HE, Ph.D. · Percent: 45.4% · SCHEDULE 13D/A
CASI Pharmaceuticals, Inc. has 16 Schedule 13D or 13G filings on record since 2025-07-23. 6 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| WEI-WU HE, Ph.D. | 58.8% | 23,985,535 | SCHEDULE 13D/A, 2026-05-18 | 2026-05-18 |
| Panacea Innovation Limited | 22.5% | 4,529,956 | SCHEDULE 13D/A, 2025-12-17 | 2025-12-16 |
| 13.8% | 2,161,571 | SCHEDULE 13G/A, 2025-07-23 | 2025-06-30 | |
| 11% | 2,255,636 | SCHEDULE 13G, 2025-11-26 | 2025-09-30 | |
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | 1,987,259 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Sparkle Byte Ltd | 5% | 1,019,852 | SCHEDULE 13D/A, 2026-01-20 | 2025-09-30 |
| 4.8% | 915,850 | SCHEDULE 13D/A, 2026-01-20 | 2025-09-30 | |
| Foresite Capital Fund VI LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Holding shares or following this stake? See who's behind CASI Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on CASI Pharmaceuticals, Inc. and the records around it.
CASI Pharmaceuticals, Inc. elsewhere on the record
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Form D filing Feb 2026
Companies that share a holder
- IDG-Accel China Growth Fund III L.P. also filed stake reports on 1 other company: Pony AI Inc. (Nov 2025)
- Panacea Venture Healthcare Fund II, L.P. also filed stake reports on 3 other companies: Atara Biotherapeutics, Inc. (May 2026), Connect Biopharma Holdings Limited (Apr 2026), Adagene Inc. (Nov 2025)
- Foresite Capital Fund VI LP also filed stake reports on 4 other companies: IRulya Therapeutics Inc. (Oct 2026), Alumis Inc. (Aug 2026), Latigo Biotherapeutics, Inc. (Aug 2026)
Watch CASI Pharmaceuticals, Inc.
Get an email when CASI Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CASI Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CASI Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CASI Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
WEI-WU HE, Ph.D.
On April 17, 2026, ETP Global III Fund L.P. purchased a convertible note with the principal amount of US$5 million as the fourth tranche of the Issuer's US$20 million convertible note financing pursuant to certain convertible note purchase agreement (the "Purchase Agreement") between ETP Global III Fund L.P. and the Issuer dated December 11, 2025. A convertible note with a principal amount of US$5 million has been issued to the Purchaser on the same date (the "Convertible Note"). The Purchaser has the right to convert such note into the Company's ordinary shares, par value US$0.0001 per share (the "Ordinary Shares") at any time from and including the 91st day after the issuance thereof to and including the maturity date at a conversion price of the volume weighted average closing price of the Company's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global III Fund L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. The descriptions of the Convertible Note are qualified in their entirety by reference to the Convertible Note itself, a copy of which is attached hereto as Exhibit B and incorporated hereby by reference in its entirety. The beneficial ownership reported hereof included Ordinary Shares that the reporting person has the right to acquire within 60 days, through the conversion of such Convertible Note, with an assumed conversion …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-18; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-23 | James Huang | 13.8% | SCHEDULE 13G/A |
| 2025-08-12 | Foresite Capital Fund VI, L.P. | 5.1% | SCHEDULE 13G/A |
| 2025-09-26 | Panacea Innovation Limited | 19.9% | SCHEDULE 13D |
| 2025-11-14 | Foresite Capital Fund VI LP | 6.3% | SCHEDULE 13G/A |
| 2025-11-26 | Chen Zhenfeng | 11% | SCHEDULE 13G |
| 2025-12-17 | Panacea Innovation Limited | 22.5% | SCHEDULE 13D/A |
| 2025-12-18 | WEI-WU HE, Ph.D. | 19.1% | SCHEDULE 13D/A |
| 2026-01-09 | WEI-WU HE, Ph.D. | 19.1% | SCHEDULE 13D/A |
| 2026-01-20 | Sparkle Byte Ltd | 5% | SCHEDULE 13D/A |
| 2026-01-20 | Ho Chi Sing | 4.8% | SCHEDULE 13D/A |
| 2026-01-29 | WEI-WU HE, Ph.D. | 34.8% | SCHEDULE 13D/A |
| 2026-02-10 | WEI-WU HE, Ph.D. | 45.4% | SCHEDULE 13D/A |
| 2026-02-13 | Foresite Capital Fund VI LP | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 9.2% | SCHEDULE 13G/A |
| 2026-03-23 | WEI-WU HE, Ph.D. | 53% | SCHEDULE 13D/A |
| 2026-05-18 | WEI-WU HE, Ph.D. | 58.8% | SCHEDULE 13D/A |
Questions about who owns CASI Pharmaceuticals, Inc.
Who owns CASI Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of CASI Pharmaceuticals, Inc.: WEI-WU HE, Ph.D. (58.8%, Schedule 13D/A, filed 2026-05-18), Panacea Innovation Limited (22.5%, Schedule 13D/A, filed 2025-12-17), James Huang (13.8%, Schedule 13G/A, filed 2025-07-23), Chen Zhenfeng (11%, Schedule 13G, filed 2025-11-26) and Venrock Healthcare Capital Partners III, L.P. (9.2%, Schedule 13G/A, filed 2026-02-17); 1 more is listed above.
Who are the largest shareholders of CASI Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of CASI Pharmaceuticals, Inc. on this page are WEI-WU HE, Ph.D. (58.8%), Panacea Innovation Limited (22.5%) and James Huang (13.8%).
When did WEI-WU HE, Ph.D. buy into CASI Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from WEI-WU HE, Ph.D. on this page is the Schedule 13D/A, filed 2025-12-18, reporting 19.1%; its latest, Schedule 13D/A filed 2026-05-18, reports 58.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for CASI Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 28, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| February 26, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| January 28, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| January 28, 2026 | Form D, private offering | $5M sold | Form D page | Source |
CASI Pharmaceuticals, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for CASI Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.